Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy

A giant disruption of the heart Certain forms of heart failure originate from genetic mutations. Understanding how the culprit mutant proteins alter normal heart function could lead to more effective treatments. One candidate is the giant protein tintin, which is mutated in a subset of patients with dilated cardiomyopathy. Through a combination of patient-derived stem cells, tissue engineering, and gene editing, Hinson et al. found that disease-associated titin mutations disrupt the function of the contractile unit in heart muscle. As a result, the heart does not respond properly to mechanical and other forms of stress. Science, this issue p. 982 Mutations in titin cause heart disease by disrupting the sarcomere, which normally helps the heart adapt to stress. Human mutations that truncate the massive sarcomere protein titin [TTN-truncating variants (TTNtvs)] are the most common genetic cause for dilated cardiomyopathy (DCM), a major cause of heart failure and premature death. Here we show that cardiac microtissues engineered from human induced pluripotent stem (iPS) cells are a powerful system for evaluating the pathogenicity of titin gene variants. We found that certain missense mutations, like TTNtvs, diminish contractile performance and are pathogenic. By combining functional analyses with RNA sequencing, we explain why truncations in the A-band domain of TTN cause DCM, whereas truncations in the I band are better tolerated. Finally, we demonstrate that mutant titin protein in iPS cell–derived cardiomyocytes results in sarcomere insufficiency, impaired responses to mechanical and β-adrenergic stress, and attenuated growth factor and cell signaling activation. Our findings indicate that titin mutations cause DCM by disrupting critical linkages between sarcomerogenesis and adaptive remodeling.

[1]  Jie-ning Zhu,et al.  MicroRNA 16 enhances differentiation of human bone marrow mesenchymal stem cells in a cardiac niche toward myogenic phenotypes in vitro. , 2012, Life sciences.

[2]  John Atherton,et al.  Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy , 2002, Nature Genetics.

[3]  P. Walker,et al.  Opportunities and Obstacles , 1953 .

[4]  R. Lafyatis,et al.  Generation of Transgene‐Free Lung Disease‐Specific Human Induced Pluripotent Stem Cells Using a Single Excisable Lentiviral Stem Cell Cassette , 2010, Stem cells.

[5]  Nenad Bursac,et al.  Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. , 2013, Biomaterials.

[6]  Wesley R. Legant,et al.  Microfabricated tissue gauges to measure and manipulate forces from 3D microtissues , 2009, Proceedings of the National Academy of Sciences.

[7]  K. Weber,et al.  The organization of titin filaments in the half-sarcomere revealed by monoclonal antibodies in immunoelectron microscopy: a map of ten nonrepetitive epitopes starting at the Z line extends close to the M line , 1988, The Journal of cell biology.

[8]  J. Thomson,et al.  Derivation of human embryonic stem cells in defined conditions , 2006, Nature Biotechnology.

[9]  Roger J Hajjar,et al.  Titin Isoform Switch in Ischemic Human Heart Disease , 2002, Circulation.

[10]  Kevin Kim,et al.  A TALEN genome-editing system for generating human stem cell-based disease models. , 2013, Cell stem cell.

[11]  J. Seidman,et al.  Construction of normalized RNA-seq libraries for next-generation sequencing using the crab duplex-specific nuclease. , 2011, Current protocols in molecular biology.

[12]  J. Seidman,et al.  Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[13]  J. Seidman,et al.  5'RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. , 2014, The Journal of clinical investigation.

[14]  L. Zentilin,et al.  Cardiomyocyte VEGFR‐1 activation by VEGF‐B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  T. Golub,et al.  MicroRNA-1 Negatively Regulates Expression of the Hypertrophy-Associated Calmodulin and Mef2a Genes , 2009, Molecular and Cellular Biology.

[16]  Thomas Boudou,et al.  A Microfabricated Platform to Measure and Manipulate the Mechanics of Engineered Cardiac Microtissues , 2012 .

[17]  G. Church,et al.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.

[18]  Jianping Fu,et al.  Assaying stem cell mechanobiology on microfabricated elastomeric substrates with geometrically modulated rigidity , 2011, Nature Protocols.

[19]  D. Vignali,et al.  Design and construction of 2A peptide-linked multicistronic vectors. , 2012, Cold Spring Harbor protocols.

[20]  D. Hedges,et al.  Dilated cardiomyopathy: the complexity of a diverse genetic architecture , 2013, Nature Reviews Cardiology.

[21]  Sanjay Kumar Microtubule assembly: Switched on with magnets. , 2013, Nature nanotechnology.

[22]  Christopher S. Chen,et al.  Cells lying on a bed of microneedles: An approach to isolate mechanical force , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Milkie,et al.  Rapid Adaptive Optical Recovery of Optimal Resolution over LargeVolumes , 2014, Nature Methods.

[24]  K. McDonald,et al.  Loaded Shortening, Power Output, and Rate of Force Redevelopment Are Increased With Knockout of Cardiac Myosin Binding Protein-C , 2003, Circulation research.

[25]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[26]  L. Mestroni,et al.  Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.

[27]  J. Harrow,et al.  Systematic evaluation of spliced alignment programs for RNA-seq data , 2013, Nature Methods.

[28]  Kumaraswamy Nanthakumar,et al.  Design and formulation of functional pluripotent stem cell-derived cardiac microtissues , 2013, Proceedings of the National Academy of Sciences.

[29]  E. Olson,et al.  MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles , 2012, Nature Reviews Drug Discovery.

[30]  M. Suematsu,et al.  Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. , 2013, Cell stem cell.

[31]  Yanjie Lu,et al.  microRNA‐124 Regulates Cardiomyocyte Differentiation of Bone Marrow‐Derived Mesenchymal Stem Cells Via Targeting STAT3 Signaling , 2012, Stem cells.

[32]  R. Hughes,et al.  Cold Spring Harbor , 2014 .

[33]  Sean P. Palecek,et al.  Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions , 2012, Nature Protocols.

[34]  Tan Ru San,et al.  Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease , 2015, Science Translational Medicine.

[35]  G. Church,et al.  Reprogramming of T cells from human peripheral blood. , 2010, Cell stem cell.

[36]  K. Weber,et al.  Repetitive titin epitopes with a 42 nm spacing coincide in relative position with known A band striations also identified by major myosin-associated proteins. An immunoelectron-microscopical study on myofibrils. , 1989, Journal of cell science.

[37]  Christopher S. Chen,et al.  Simple approach to micropattern cells on common culture substrates by tuning substrate wettability. , 2004, Tissue engineering.

[38]  Wolfgang A Linke,et al.  Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. , 2007, Cardiovascular research.